Efficacy of Intermittent fasting in patients with non-alcoholic fatty liver disease.

Dr Deepankshi Aggarwal0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年1月9日

试验速览

暂无简介。

•1) NAFLD patients will be defined by the evidence of hepatic steatosis, either by ultrasound or Fibroscan with no significant alcohol consumption (less than 20g/day) and after excluding alternate causes of steatosis and/or raised hepatic transaminases (including but not limited to drug intake, chronic Hepatitis B and C, autoimmune hepatitis, hemochromatosis, Wilsonâ??s disease, celiac disease).
•2) Overweight and Class I Obese patients as per Asia-Pacific criteria (BMI greater than or equal to 23 ,and less than 30 Kg/m2).
•3) Consent to participate in study.

•1) Patients who are not willing to give consent for the study.
•2) Patients having Type 2 Diabetes mellitus.
•3) Patients who have evidence of cirrhosis liver on ultrasound or Fibroscan (LSM greater than or equal to 12.5 kPa).
•3) Patients with history of hepatic decompensation.
•4) Patients with class II obesity as per Asia-Pacific criteria (BMI greater than or equal to 30 Kg/m2).
•5) Patients taking weight loss drugs.
•6) Patients taking pharmacotherapy for NASH (e.g. Pioglitazone, Vit E and Saroglitazar).
•7) Patients with post bariatric surgery status.
•8) Pregnant / lactating females. Those non pregnant female patients recruited in the study who will conceive during the study period will be excluded from the study.

发起方

Dr Deepankshi Aggarwal